110.37
2.03 (1.87%)
| Previous Close | 108.34 |
| Open | 106.70 |
| Volume | 54,858 |
| Avg. Volume (3M) | 226,982 |
| Market Cap | 2,689,275,392 |
| Price / Earnings (Forward) | 21.98 |
| Price / Sales | 1.65 |
| Price / Book | 1.90 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2024 - 9 Aug 2024 |
| Profit Margin | -4.74% |
| Operating Margin (TTM) | 3.58% |
| Diluted EPS (TTM) | -4.56 |
| Quarterly Revenue Growth (YOY) | 6.50% |
| Total Debt/Equity (MRQ) | 81.03% |
| Current Ratio (MRQ) | 2.29 |
| Operating Cash Flow (TTM) | 255.11 M |
| Levered Free Cash Flow (TTM) | 280.08 M |
| Return on Assets (TTM) | 0.66% |
| Return on Equity (TTM) | -5.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | ICU Medical, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.20 |
|
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 7.84% |
| % Held by Institutions | 101.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 209.00 (Keybanc, 89.36%) | Buy |
| Median | 204.50 (85.29%) | |
| Low | 200.00 (Jefferies, 81.21%) | Buy |
| Average | 204.50 (85.29%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 170.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 11 Dec 2024 | 200.00 (81.21%) | Buy | 166.19 |
| 14 Oct 2024 | 183.00 (65.81%) | Hold | 180.30 | |
| Keybanc | 13 Nov 2024 | 209.00 (89.36%) | Buy | 174.81 |
| 15 Oct 2024 | 198.00 (79.40%) | Buy | 179.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance |
| 12 Nov 2024 | Announcement | ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America |
| 06 Nov 2024 | Announcement | ICU Medical to Participate at the UBS Global Healthcare Conference |
| 28 Oct 2024 | Announcement | ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |